August 31, 2020 Comments Off on Investor Alert: Protagenics Therapeutics (PTIX) fka Atrinisic, Inc. Blog, Current Investigations

Investor Alert: Protagenics Therapeutics (PTIX) fka Atrinisic, Inc.

Investor Alert: Protagenics Therapeutics (PTIX)  fka Atrinisic, Inc., featured by top securities fraud attorneys, The White Law Group

Concerned about your investment in Protagenics Therapeutics?

Are you concerned about your investment in Protagenics Therapeutics (PTIX)? If so, the securities attorneys at The White Law Group may be able to help you by filing a FINRA Dispute Resolution claim against the brokerage firm that sold you the investment.

Protagenic Therapeutics, Inc., (formerly known as Atrinisic Inc.),  a biotechnology company, reportedly specializes in the discovery and development of therapeutics to treat central nervous system disorders, according to MarketWatch.

The company filed a form D to raise capital from investors in 2016 for the offering Atrinsic, Inc., according to filings with the SEC. The total offering amount sold was purportedly $3,468,750.

According to the SEC filings, at closing, Atrinsic Inc., a wholly-owned subsidiary, merged with and into Protagenic Therapeutics, Inc., with PTI surviving the merger. Among other merger considerations issued to PTI security holders, PTI stockholders received shares of stock.

According to Market Watch, as of August 31, shares of PTIX are down more than 22% in the past 12 months. 

Filing a Complaint against your Brokerage Firm

The White Law Group is investigating the liability that FINRA registered brokerage firms may have for improperly recommending high-risk investments to investors.

The problem with technology investments such as Protagenics Therapeutics is that they typically involve a high degree of risk. The research and development process for pharma and biotech companies often involves costly and lengthy testing trials that yield specific data. If the expected data or end points are not met, that could be bad news for investors.

Without a strong understanding of the company and its basic operations, investors may be looking at serious losses.

Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.

If you have concerns regarding investment losses in Protagenics Therapeutics (fka Atrinsic Inc.)  please call the securities attorneys at The White Law Group for a free consultation at 888-637-5510.

The White Law Group, LLC is a national securities fraud, securities arbitration, investor protection, and securities regulation/compliance law firm with offices in Chicago, Illinois and Franklin, Tennessee.

For more information on The White Law Group and its representation of investors in FINRA arbitration claims, visit https://www.whitesecuritieslaw.com.

 

Comments are closed.